Florida clade 1 equine influenza virus in France

Preliminary results from a large scale seroepidemiological study we conducted in 2018, involving 3000 French horses, reveals that equine influenza vaccination is well established, with 90 per cent of the studied population possessing antibody titres above the protection threshold against clinical signs of disease and 60 per cent virus shedding.1 The predominant use in France of the recombinant canarypox virus equine influenza vaccine ProteqFlu-Te (Boehringer Ingelheim/Merial), the only fully updated equine influenza vaccine licensed in the EU with DIVA (differentiating infected from vaccinated animal) capability, allowed us to confirm that the measured equine influenza immunological status was mostly attributed to equine influenza vaccination, with little immunological …